BTK and amyotrophic lateral sclerosis: BTK inhibition might provide therapeutic benefit in amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, whose pathophysiology is thought to be multifactorial, involving neuroinflammation, oxidative stress, disrupted protein homeostasis, mitochondrial dysfunction, and glutamate excitotoxicity.